Prelude Therapeutics Incorporated
PRLD
$1.00
$0.117313.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -11.67% | 10.97% | 7.11% | -10.53% | 4.97% |
| Total Depreciation and Amortization | -11.04% | 20.74% | -10.40% | 6.10% | 28.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.76% | -41.65% | 6.59% | 16.81% | -18.88% |
| Change in Net Operating Assets | -260.39% | 559.49% | -115.38% | 216.56% | -240.06% |
| Cash from Operations | -65.02% | 24.00% | -18.38% | 27.47% | -34.83% |
| Capital Expenditure | 11.32% | 15.87% | 82.45% | -24.22% | 74.40% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 180.70% | 105.36% | -59.23% | -15.97% | 255.44% |
| Cash from Investing | 181.16% | 106.07% | -58.91% | -16.34% | 303.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.65% | -2.03% | -54.17% | -- | -- |
| Issuance of Common Stock | -- | 121.43% | -78.21% | 12,750.00% | -99.99% |
| Repurchase of Common Stock | 28.57% | 46.15% | 27.78% | -12.50% | -1,500.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 69.05% | -- | -- |
| Cash from Financing | -370.59% | 74.05% | -322.03% | 521.43% | -100.06% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,974.25% | 108.03% | -634.89% | 634.42% | -106.22% |